Drugs / EMTRICITABINE, (+/-)-
EMTRICITABINE, (+/-)-
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00040300 | Jun → Dec 2002 | HIV infectious disease | Pharmasset | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00121979 | Sep 2004 → Mar 2006 | HIV infectious disease | Pharmasset | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMTRICITABINE, (+/-)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL161381 ↗ |
| Known as | Ftc, dl- | ChEMBL registry synonym — accepted as the source's own label CHEMBL161381 ↗ |
| Known as | PSI-5004 | ChEMBL registry synonym — accepted as the source's own label CHEMBL161381 ↗ |
| Known as | Racivir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00121979 ↗ |
| Known as | RCV | “Racivir ® (RCV) is an experimental drug” NCT00121979 ↗ |
| Modality | Other / unclassified | “Racivir, a non-nucleoside reverse transcriptase inhibitor” NCT00121979 ↗ |
| Route | Oral | “They will be asked to take one tablet from each bottle once a day by mouth” NCT00121979 ↗ |